US Activist Hedge Fund Institutional SEC 13D 13G — October 15, 2026

15-10-2026

ARC Group International Limited (AGIL), together with its parent ARC Group Limited and CEO/director Abraham Cinta, filed a Schedule 13G reporting beneficial ownership of 4,946,413 shares of Class A Common Stock of Exascale Labs Holdings Inc. (formerly D. Boral ARC Merger Corp, ticker XLAB), equal to 14.7% of the 33,689,050 Class A shares outstanding per the issuer's 10-K filed September 28, 2026. The filing reports a holding as of October 7, 2026 under Rule 13d-1(c), and certifies the shares were not acquired to change or influence control of the issuer. Notably, 1,000,000 of the reported shares are subject to a June 2026 agreement to sell to Publico Partners Ltd, for which AGIL has already received payment but has not yet delivered the shares.

• · Reporting persons' address is c/o ARC Group International Limited, Hong Kong; Mr. Cinta is reported as a citizen/resident of Mexico
• · Sole voting and dispositive power is reported for AGIL and ARC Group as shared; Mr. Cinta reports sole power over the same 4,946,413 shares
• · Pending 1,000,000-share sale to Publico Partners Ltd could reduce the reporting persons' stake upon delivery, which would lower the reported percentage
• · Filing is a LIVE Schedule 13G under Rule 13d-1(c), a passive-investor filing, with a certification against control intent

15-10-2026

Mitsui & Co., Ltd. and its U.S. subsidiary Mitsui & Co. (U.S.A.), Inc. filed Amendment No. 15 to their Schedule 13D disclosing their participation in an Investor Group with Penske Corporation and Penske Automotive Holdings Corp. that signed a Merger Agreement on October 15, 2026 with Motown Acquisition Corp. to take Penske Automotive Group, Inc. (PAG) private. Each outstanding share not held by the Investor Group (excluding treasury shares, Buyer-held shares, and perfected appraisal shares) would be converted into the right to receive $212.00 in cash. The Reporting Persons report beneficial ownership of 13,322,205 shares, or 20.3% of common stock, and the transaction is subject to a majority-of-outstanding and majority-of-disinterested-stockholder vote, regulatory approvals, and other customary conditions, with a termination fee of $383 million payable in specified circumstances.

• · Merger consideration is cash-only at $212.00 per share; Investor Group members retain continuing equity via Excluded Shares in the Surviving Corporation.
• · Closing requires approval by a majority of outstanding shares and a separate majority of votes cast by disinterested stockholders (Unaffiliated Company Stockholders).
• · Merger is not subject to a financing condition; Outside Date is 11:59 p.m. New York City time on October 15, 2027.
• · Termination fee of $383M applies to a Superior Proposal termination, an Adverse Recommendation Change, or certain failed-closing scenarios followed by a Takeover Proposal within 12 months (threshold reduced to 50%).
• · Special Committee of independent, disinterested directors unanimously deemed the transaction fair and advisable; affiliated directors recused.
• · Reporting Persons disclaim group beneficial ownership of shares held by other Stockholders Agreement parties.
• · Amendment No. 15 follows Amendment No. 14 filed July 22, 2026, indicating a series of recent disclosures tied to the transaction.

15-10-2026

Third Point LLC and Daniel S. Loeb filed a Schedule 13D disclosing beneficial ownership of 5,126,511 shares of Strata Critical Medical, Inc. (SRTAW) common stock, approximately 5.8% of outstanding shares, and stating the stake is held for investment purposes. The filing signals activist intent: the Reporting Persons believe the company is undervalued, its business is not of a scale to support current overhead, management incentive options are misaligned with shareholder value, and the company should explore strategic alternatives including a potential sale. Recent trading shows net buying in October 2026 at prices of roughly $4.53-$4.55 per share, with the Funds having invested $24,452,374 in total.

• · Reporting Persons previously held a Schedule 13G filed August 11, 2025, amended November 14, 2025; this 13D reflects a change in intent toward active engagement.
• · Recent activity includes two small sales on 08/31/2026 and 09/30/2026, followed by net accumulation on 10/12/2026 and 10/13/2026 at prices around $4.53-$4.55, below prior sale prices of $5.11-$5.66.
• · Reporting Persons state they may communicate with management and the Board on operational, governance, and strategic matters, and may buy or sell additional shares or derivatives.
• · Shares are held through margin accounts, and some positions may be pledged as collateral for debit balances.

15-10-2026

Alex Meruelo and the Alex Meruelo Living Trust jointly filed a Schedule 13G reporting beneficial ownership of 6,001,029 shares of FuelCell Energy Inc (FCELB) common stock, equal to approximately 7.5% of the 79,954,196 shares outstanding as of August 27, 2026. The Trust directly holds 5,960,529 shares, and Meruelo may be deemed to beneficially own an additional 40,500 shares held by his spouse, Liset Meruelo, which he disclaims except to the extent of any voting or investment power. The filing is made under Rule 13d-1(c), and the reporting persons certify the shares were not acquired to change or influence control of the issuer.

• · Ownership is reported as of October 13, 2026, with the reporting date of the event listed as October 7, 2026.
• · The Trust is a revocable California trust; Meruelo is its sole trustee and the reporting persons' principal office is in Reno, Nevada.
• · The filing is a joint filing under a Joint Filing Agreement dated October 15, 2026 (Exhibit 99.1), under Rule 13d-1(c), and states the shares are not held to change or influence control of the issuer.
• · Liset Meruelo has the right to receive dividends and sale proceeds on her 40,500 shares, per the filing.

15-10-2026

Ruen Hua Dyeing & Weaving Co., Ltd. filed a Schedule 13D reporting beneficial ownership of 9,867,015 Gogoro Inc. ordinary shares, representing 21.92% of the class based on 45,009,640 shares outstanding. The position includes 8,616,603 shares purchased at the October 13, 2026 Closing under a share purchase agreement dated October 7, 2026 at US$2.48 per share (aggregate US$21,369,175.44), plus 1,250,412 shares held by entities Ruen Hua controls. The filing is a passive-to-strategic investment disclosure; it contains no reported declines or underperforming metrics, and the purchase was funded from Ruen Hua's working capital.

• · Ruen Hua is a Taiwan textile weaving company; its directors include the Gogoro chairman and a Gogoro director, indicating close governance ties to the issuer.
• · Ruen Hua has agreed not to pursue acquisitions, tender or exchange offers, proxy solicitation, or group formation with Gogoro without the issuer's consent (standstill provisions).
• · The issuer granted Ruen Hua registration rights under the Securities Act, including demand, piggyback, and shelf registration rights effective at Closing.
• · The filing states the position was acquired for investment purposes, and Ruen Hua reserves the right to change its intentions, including future purchases, dispositions, or extraordinary transactions.
• · Ruen Hua's disclosed Closing and fund transfer occurred October 13, 2026, while the SC 13D filing date is October 15, 2026.
• · Ruen Hua reports no sole voting or dispositive power over 1,250,412 shares, which are attributed through controlled entities on a shared basis.

15-10-2026

Citadel Securities GP LLC and affiliated Citadel entities, including Kenneth Griffin, filed a joint Schedule 13G reporting beneficial ownership of 5,409,576 shares of First Solar, Inc. (FSLR), approximately 5.0% of outstanding common stock, as of September 30, 2026. The filing is a passive, ordinary-course disclosure under Rule 13d-1(b), with the reporting persons certifying no intent to influence control of the issuer. Holdings are split between Citadel Securities LLC (4,433,406 shares, 4.1%) and Citadel Securities Group LP/GP LLC (5,375,954 shares, 5.0%), with a further 33,622 shares (0.0%) attributed to Citadel Advisors entities.

• · Filing is a joint Schedule 13G under Rule 13d-1(b) covering six Reporting Persons; the reporting persons certify the shares were acquired and are held in the ordinary course of business without intent to change or influence control of the issuer.
• · Shares are held of record by CWSI II LLC, with Citadel Securities and Citadel Securities Principal Strategies LLC also holding shares; Citadel Advisors is portfolio manager for CWSI II LLC.
• · Percentage calculations are based on 107,469,788 shares outstanding as of July 24, 2026, per the issuer's Form 10-Q.

15-10-2026

HOLD Alapkezelo Zrt., a Hungarian investment fund management company, filed a Schedule 13G (LIVE) reporting beneficial ownership of 4,157,791 shares of Protalix BioTherapeutics, Inc. common stock, representing approximately 5.2% of the outstanding shares. The filing certifies the holdings were not acquired to influence or change control of the issuer. As a passive 13G filing, it discloses a stake crossing the 5% threshold without indicating any intent to pursue control or activism.

• · Event date (date of acquisition/triggering event) was October 14, 2026; filing date October 15, 2026
• · Filing is a LIVE Schedule 13G, indicating an initial or amended passive beneficial ownership report
• · Reporting person holds sole voting and sole dispositive power over all 4,157,791 shares; no shared power reported
• · Filer certifies holdings are not for the purpose or effect of changing or influencing control of the issuer
• · Filer is a Hungarian investment fund management company located in Budapest

15-10-2026

M&G Plc, through wholly-owned intermediate holding companies and on behalf of certain subsidiaries, filed a Schedule 13G reporting beneficial ownership of 17,380,242 Class A ordinary shares of Atour Lifestyle Holdings Ltd (ATAT), representing 5.20% of the class as of September 30, 2026. The filer reports sole voting power over 16,265,283 shares and shared dispositive power over 17,380,242 shares, and certifies the holdings were acquired in the ordinary course of business without intent to influence control. The filing is a passive institutional ownership disclosure filed under Rule 13d-1(b), with no transaction or control-change details disclosed.

• · Filing is a Schedule 13G under Rule 13d-1(b), indicating a passive institutional holder rather than an activist or control-seeking investor
• · Reported ownership is as of September 30, 2026, with the filing dated October 15, 2026
• · Ownership is held for investment vehicles for which M&G Plc reporting persons act as investment manager, with disclaimer of beneficial ownership except to the extent of pecuniary interest

15-10-2026

Empery Asset Management, LP and its managing principal Ryan M. Lane filed a Schedule 13G reporting beneficial ownership of 3,346,275 shares of Dyadic International Inc. (DYAI) common stock, representing 8.35% of the 40,063,703 shares outstanding as of September 10, 2026. The filing is made under Rule 13d-1(b) as a passive institutional holding, with the reporting persons certifying the shares were not acquired to influence control of the issuer.

• · Position is held as of September 30, 2026, per the filing's event date
• · Filing type is an initial LIVE Schedule 13G under Rule 13d-1(b), indicating a qualified institutional investor rather than an activist 13D filing
• · Reporting persons disclaim beneficial ownership of shares held by the other reporting person and certify no intent to influence control
• · Filer is based at 1 Rockefeller Plaza, New York, NY; the issuer is headquartered in Jupiter, FL
• · Filing was signed by Ryan M. Lane on October 15, 2026, with a Joint Filing Agreement attached as Exhibit 99.1

15-10-2026

Empery Asset Management, LP and managing member Ryan M. Lane filed an amended Schedule 13G reporting beneficial ownership of 2,241,537 Annovis Bio common shares issuable upon warrant exercise, equal to 4.99% of outstanding shares after the contractual 4.99% blocker. The filing reflects a position as of 09/30/2026, is made under Rule 13d-1(b) as passive institutional holders, and includes a certification that the shares are not held to influence control of the issuer.

• · Filing is an amendment (SCHEDULE 13G/A) referencing a prior LIVE filing, accession 0000919574-26-004667.
• · Reporting persons are filing under Rule 13d-1(b), an institutional investor pathway, and checked the passive-intent certification.
• · Holdings are through Empery Funds managed by Empery Asset Management as investment manager; Ryan M. Lane disclaims beneficial ownership beyond his own interest.
• · Company address: 101 Lindenwood Drive, Suite 225, Malvern, PA 19355; Empery address: 1 Rockefeller Plaza, Suite 1205, New York, NY 10020.

15-10-2026

Empery Asset Management, LP and its managing member Ryan M. Lane filed a Schedule 13G on October 15, 2026 reporting beneficial ownership of 468,750 shares of Femasys Inc. (FEMY) common stock, equal to 5.6% of outstanding shares, held through funds managed by Empery as investment manager. The filing is a passive 13G under Rule 13d-1(b) and includes a certification that the securities were not acquired to influence control of the issuer. No change of control, acquisition deal, or regulatory action is disclosed.

• · Filing is a passive Schedule 13G (Rule 13d-1(b)) with Empery reporting as an investment adviser (IA) and Lane as a holding company/control person (HC)
• · Reporting persons disclaim beneficial ownership of shares held by other reporting persons, except to the extent of pecuniary interest

15-10-2026

Kennedy Capital Management LLC filed an amended Schedule 13G reporting beneficial ownership of 230,418 shares of Park Dental Partners, Inc. (PARK), representing 4.8% of the outstanding common stock as of August 14, 2026. The filing is made under Rule 13d-1(b) by Kennedy as an investment adviser (IA) holding the shares in the ordinary course of business, with sole voting and dispositive power over all reported shares and a certification that the position is not held to influence control of the issuer.

• · Event date of August 14, 2026 is the date of the triggering ownership change; the filing itself is dated October 15, 2026
• · Filer is a Delaware-organized investment adviser based in St. Louis, Missouri, filing under Rule 13d-1(b) (qualified institutional investor)
• · Reported shares: 230,418 with no shared voting or dispositive power
• · Issuer is a Minnesota corporation headquartered in Roseville, Minnesota, with CUSIP 700402100

15-10-2026

Bleichroeder LP, together with its parent Bleichroeder Holdings LLC and controlling person Andrew Gundlach, filed Amendment No. 1 to its Schedule 13D on MDxHealth SA, reporting beneficial ownership of 30,571,922 ordinary shares, or 32.04% of outstanding shares. The amendment discloses open-market sales over the 60 days prior to October 15, 2026, with the reporting persons' cost basis at $46,267,320.19 and recent sales prices falling from about $0.67 to as low as $0.51 before recovering to $0.62 on October 13, 2026. The filing reports sales only, so the reporting persons' stake has been reduced over this period, though the amendment itself does not state the prior holding.

• · Schedule I discloses 17 open-market sale transactions between September 17 and October 13, 2026, with the largest single-day sale of 268,645 shares on October 13, 2026 at $0.6217
• · Lowest disclosed sale price was $0.5104 on September 29, 2026, when 136,908 shares were sold
• · The amendment amends an original Schedule 13D filed August 11, 2026, and restates Items 3 and 5(a)-(c)

15-10-2026

Chia-Lin Simmons, CEO, President and director of LogicMark, Inc. (LGMK), filed Amendment No. 1 to Schedule 13D reporting an exit: she now beneficially owns 0 shares (0.0%) following the closing of the merger on October 13, 2026. Under the July 31, 2026 Merger Agreement with Langham Project, LLC and Langham Merger Sub, Inc., each share of common stock was cancelled and converted into the right to receive $1.31 in cash, and the Issuer now survives as a wholly owned subsidiary of Parent. The filing is an exit filing with no new positive or negative operational performance disclosed.

• · Merger Agreement dated July 31, 2026; Merger closed October 13, 2026, the same date the Reporting Person ceased to be a >5% beneficial owner
• · Filing is an exit filing; the original Schedule 13D was filed August 3, 2026
• · Issuer will survive as a wholly owned subsidiary of Langham Project, LLC, so LGMK public common stock is no longer outstanding in the same form

15-10-2026

Fairmount Funds Management LLC, together with affiliated funds Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest VII L.P. and managers Peter Harwin and Tomas Kiselak, filed a joint Schedule 13D disclosing beneficial ownership of 858,789 shares of Alaunos Therapeutics common stock, or 19.99% of the outstanding common stock, as of October 13, 2026. The position includes 687,789 newly issued common shares from a recent financing plus 171,000 shares issuable on conversion of Series C preferred stock held by Co-Invest. Substantially larger additional holdings in Series B and Series C preferred stock are excluded from the reported figure due to a 19.99% beneficial ownership limitation, which would reduce to 9.99% once the group falls to 9.0% or less of common stock.

• · The Reporting Persons' reported stake is capped at 19.99% by a contractual beneficial ownership limitation; the underlying preferred holdings would convert into roughly 105.3M, 52.2M and 16.6M additional common shares, far exceeding the outstanding common base of about 4.1M shares.
• · Fund II and Co-Invest disclaim beneficial ownership, having delegated voting and dispositive power to Fairmount with revocation requiring 61 days' notice; Harwin and Kiselak disclaim beneficial ownership except for Section 13(d) purposes.
• · Reported purchase cost of $100,199,073.47 was funded from the Reporting Persons' general working capital, with no indication of intent to seek control or board representation in the excerpt provided.

15-10-2026

Gal Eido, Riskified's co-founder and an Israeli citizen, filed an amended Schedule 13G reporting beneficial ownership of 13,707,781 Class A Ordinary Shares as of September 30, 2026, equal to 11.3% of the class. The position combines 4,532,293 common shares held directly, 62,188 shares underlying restricted stock units vesting by November 29, 2026, and 9,113,300 shares underlying Class B shares convertible at his election by November 29, 2026. The filing reports sole voting and dispositive power and is made under Rule 13d-1(d), indicating a passive, pre-2020 holder rather than an active control filing.

• · Filing made under Rule 13d-1(d), typically applicable to holders who acquired shares before the issuer's registration and are not seeking control
• · Ownership is reported as sole voting and sole dispositive power with no shared power
• · Percentage calculation assumes conversion of Class B shares into Class A within 60 days, which materially affects the reported 11.3% figure
• · Filing type is Amendment 6 of Schedule 13G, indicating ongoing changes in reported holdings over time
• · Reporting person's principal business address is c/o Riskified, New York, NY

15-10-2026

Ripple Labs Inc., its controlling shareholder Christian A. Larsen, and the Larsen Lam Children's Remainder Trust jointly disclosed beneficial ownership of Class A common stock of Evernorth Holdings Inc. under Schedule 13G (Rule 13d-1(c), passive investor filing). Aggregate reported holdings are 2,340,249 shares for Chris Larsen (9.9%), 1,678,382 shares for Ripple (7.1%), and 661,867 shares for the Larsen Trust (2.8%), based on 23,638,882 Class A shares outstanding. The filing is a passive disclosure and includes a certification that the shares are not held to influence control of the issuer; the event date is October 9, 2026, and the filing was signed October 15, 2026.

• · Filing type is Schedule 13G under Rule 13d-1(c), indicating a passive investor rather than a 13D activist filing
• · Chris Larsen may be deemed to beneficially own shares held by Ripple through his controlling stake and shares held by the Larsen Trust as trustee, but disclaims beneficial ownership beyond his pecuniary interest
• · Joint Filing Agreement dated October 13, 2026, filed as Exhibit 99.1 under Rule 13d-1(k)(1)
• · Reporting persons have sole voting and dispositive power over their respective shares, with no shared voting or dispositive power reported
• · Evernorth Holdings Inc. is a Nevada-incorporated company classified under SIC 6221 (commodity contracts brokers and dealers) with a San Francisco address at 600 Battery Street, the same address as Ripple

15-10-2026

Helena Global Investment Opportunities 1 Ltd. filed a Schedule 13G reporting beneficial ownership of 7,345,809 common shares of DevvStream Corp. (DEVS), representing 14.07% of the 52,227,270 shares outstanding as of October 14, 2026. The filer certifies the shares were acquired and are held without the purpose or effect of changing or influencing control of the issuer, and reports sole voting and dispositive power over all shares with no shared power.

• · Event date of acquisition/change in ownership reported as 09/08/2026, with filing made under Rule 13d-1(c) (passive investor certification)
• · Filer is a Cayman Islands entity; DevvStream Corp. was formerly named Focus Impact Acquisition Corp. (name change dated 2021-03-31)
• · Filing is a LIVE submission, indicating an initial or amended 13G reporting event for the period

15-10-2026

J. Wood Capital Advisors LLC and its managing member Jason Wood filed a Schedule 13G/A reporting beneficial ownership of 25,974 shares of common stock of Korsana Biosciences, Inc. (formerly Cyclerion Therapeutics, Inc.) as of September 30, 2026, representing 0.1% of outstanding shares. The filing is a passive-investor disclosure under Rule 13d-1(c), with the reporting persons certifying the shares were not acquired to influence control of the issuer.

• · Filing was made under Rule 13d-1(c), indicating passive investor status rather than an intent to influence control
• · Reporting persons are J. Wood Capital Advisors LLC (California LLC, record holder) and Jason Wood (U.S. citizen, managing member), both based in Santa Rosa, CA
• · Issuer's name changed from Cyclerion Therapeutics, Inc. to Korsana Biosciences, Inc. (CUSIP 23255M303); the filing is under the ticker CYCN per the request
• · Filing type is an amendment to a prior Schedule 13G, with ownership reported as of a September 30, 2026 event date

15-10-2026

ISQ Global Fund II GP LLC and affiliated reporting persons (I Squared Capital, ISQ Holdings, Wahba Sadek, Gautam Bhandari) filed Amendment No. 17 to their Schedule 13D on Kinetik Holdings Inc. (KNTK). The filing reports beneficial ownership of 15,169,892 Class A shares, approximately 15.8% of outstanding Class A common stock, which includes redeemable Common Units and paired Class C shares and shares issuable under a Contribution Allocation Agreement. On October 13, 2026, Buzzard Midstream LLC redeemed 2,000,000 Common Units for Class A shares and sold them in a block trade at $54.77 per share.

• · Filing is Amendment No. 17 to the Original Schedule 13D first filed March 4, 2022, with a prior amendment on September 21, 2026
• · Reporting persons disclaim being a 'group' with Blackstone, Apache and their affiliates under Section 13(d)
• · Sales by reporting persons are otherwise limited to the October 13, 2026 block trade since Amendment No. 16

15-10-2026

Orca Capital AG filed a Schedule 13G reporting beneficial ownership of 1,112,788 Class A ordinary shares of China SXT Pharmaceuticals, Inc., representing 9.9% of the outstanding Class A shares, as of October 8, 2026. The stake is passive (Rule 13d-1(c)) and is subject to a 9.99% beneficial ownership blocker on the associated pre-funded and common warrants, which together could otherwise be exercised for 887,212 and 2,000,000 additional shares respectively. The filing carries no reported negative or flat performance data, as it is an ownership disclosure rather than a financial report.

• · Filing was made under Rule 13d-1(c), a passive investor designation, with the reporting person certifying the shares are not held to influence control of the issuer
• · The 9.99% blocker caps Orca Capital AG's ability to exercise warrants, so reported ownership would rise above 9.9% only if the blocker were waived or reduced

15-10-2026

Orca Capital AG filed a Schedule 13G reporting beneficial ownership of 299,655 Class A ordinary shares of DarkIris Inc. (DKI), representing 11.7% of the outstanding Class A shares as of October 8, 2026. The position is held passively under Rule 13d-1(c), with the filer certifying it is not acquired to influence control. Ownership percentage excludes warrants subject to a 9.99% beneficial ownership blocker.

• · Filing reflects a LIVE position with a trade/event date of October 8, 2026, filed October 15, 2026 under Rule 13d-1(c) (passive investor)
• · Issuer is a Hong Kong-based (Sheung Wan) company classified under SIC 7372 Prepackaged Software, with CUSIP G2657S103
• · Filer Orca Capital AG is located in Pfaffenhofen, Germany and is classified as a corporation (CO)
• · Filer certifies holdings are not for the purpose of changing or influencing control of the issuer

15-10-2026

ATW Partners Opportunities Management, LLC and affiliated reporting persons (Sandtrap Opportunities LLC, Sandtrap Opportunities II LLC, ATW Opportunities Master Fund II, LP, ATW Master Fund V LP, Kerry Propper, and Antonio Ruiz-Gimenez) filed a Schedule 13G/A reporting beneficial ownership of 137,625 shares of TruGolf Holdings, Inc. Class A Common Stock, representing 9.9% of the class. The position reflects shares issuable within 60 days upon conversion or exercise of Series A/B Preferred Stock and warrants, subject to a 9.99% beneficial ownership blocker. The filing is made under Rule 13d-1(c) as a passive investor and includes a certification that the securities are not held to influence control of the issuer.

• · Filing is a Schedule 13G/A filed under Rule 13d-1(c), indicating a passive investor position rather than an activist filing
• · Reported event date is October 8, 2026, per the filing's Item 2 date of event which requires acquisition
• · Holdings are subject to a 9.99% blocker, so the reported 9.9% reflects capped conversion rights rather than current outstanding shares; the reporting persons currently hold 0 shares with sole voting and dispositive power
• · Each reporting person reports shared voting and dispositive power over 137,625 shares, with the Adviser and control persons deemed to share power through the Holding Companies
• · Reporting persons disclaim beneficial ownership beyond their pecuniary interest
• · Joint filing statement executed under Rule 13d-1(k)(1), with signatures dated October 15, 2026
• · Issuer is headquartered in Centerville, Utah per Item 2, while the filer's business address is in New York, NY; the cover page lists a Plantation, FL address for the issuer's business records

15-10-2026

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reported beneficial ownership of 1,362,730 shares of Tenax Therapeutics, Inc. (TENX) common stock, representing 3.6% of the class as of September 30, 2026, via a Schedule 13G/A filed October 15, 2026. The filing is a passive ownership disclosure under Rule 13d-1(c) with a certification that the shares were not acquired to influence control of the issuer.

• · Filing is a Schedule 13G/A (amendment), indicating a change in a previously reported passive stake
• · Event date for the ownership position is September 30, 2026; filing date is October 15, 2026
• · Reporting persons hold 0 shares with sole voting or dispositive power and 1,362,730 shares with shared voting and dispositive power
• · Filing is made under Rule 13d-1(c), a passive investor designation, and the certification states the holdings are not for the purpose of changing or influencing control
• · Ownership is held through entities under the control of Millennium Management LLC and/or other investment managers, and the filing disclaims an admission of beneficial ownership
• · Joint filing agreement dated October 14, 2026 covers all three reporting persons

15-10-2026

Drew Holdings Ltd. and its controlling shareholder Mr. Tor Olav Troim filed Amendment No. 1 to Schedule 13D disclosing open-market purchases of Borr Drilling Limited (BORR) common shares on October 13, 14, and 15, 2026, totaling 2,750,000 shares at prices between approximately $4.27 and $4.93. Following these purchases, the Reporting Persons beneficially own 40,117,808 common shares, or 13.1% of the 307,391,018 shares outstanding. The filing is a routine beneficial ownership update with no disclosed change in control intent or regulatory action.

• · Drew Holdings Ltd. purchased 1,500,000 shares on Oct 13, 2026 at avg $4.9344, 750,000 shares on Oct 14, 2026 at avg $4.2700, and 500,000 shares on Oct 15, 2026 at avg $4.5983
• · Amendment amends the initial Schedule 13D filed October 13, 2026
• · No other transactions in the Common Shares by the Reporting Persons in the past 60 days beyond those disclosed

15-10-2026

Schedule 13D/A filed by Jakhongir Abidovich Artikkhodjaev and Tourism and Entertainment Group LLC (TEG LLC) reports beneficial ownership of 128,506,935 shares of TEG Overseas, Inc. (formerly StageWise Strategies Corp., STWI), equal to approximately 68.3% of 188,142,768 shares outstanding. The increase follows a Share Exchange Agreement dated October 6, 2026, under which the issuer acquired 99.99999012% of TEG SPV, LLC in exchange for 183,098,434 issuer shares, closing October 13, 2026. The filing also describes a notable internal discrepancy: the agreement allocates 124,506,935 exchange shares to TEG LLC, while the reported beneficial ownership is 128,506,935 shares.

• · Filing reports a 4,000,000-share discrepancy between TEG LLC's allocated Exchange Shares (124,506,935) and its reported beneficial ownership (128,506,935)
• · Share Exchange Agreement dated October 6, 2026; Share Exchange Transaction closed October 13, 2026, but the Item 4 disclosure date is listed as 10/13/2026 while the agreement was filed on Form 8-K on October 8, 2026
• · Issuer name changed from StageWise Strategies Corp. (name change dated October 31, 2023) to TEG Overseas, Inc.; subject company's business address is in Tashkent, Uzbekistan
• · Agreement filed as Exhibit 2.1 to the issuer's Form 8-K, incorporated by reference

15-10-2026

Saba Capital Management, L.P., together with Saba Capital Management GP, LLC and Boaz R. Weinstein, filed Amendment No. 10 to Schedule 13D reporting beneficial ownership of 2,696,154 common shares of Japan Smaller Capitalization Fund, Inc. (JOF), or approximately 10.57% of outstanding shares. The filing discloses open-market purchases of roughly 2.7 million shares...

• · Schedule A lists all trades as open-market buys, with prices ranging from $12.33 to $12.68 per share from 9/22/2026 through 10/14/2026.
• · Reporting persons state the funds may receive dividends and sale proceeds from the shares, and disclaim beneficial ownership for Section 13 purposes.
• · Ownership is held with zero sole voting or dispositive power and 2,696,154 shares shared power to vote and dispose.

15-10-2026

Psyence Labs Ltd. filed Amendment No. 1 to its Schedule 13D on the Issuer PSYENCE BIOMEDICAL LTD. (PBMWW) disclosing that on October 1, 2026 it acquired 1,497,500 Common Shares under a Share-for-Share Swap and Nomination Agreement dated September 21, 2026, bringing its total beneficial ownership to 2,643,659 Common Shares, or approximately 49.75% of the 5,314,048 Common Shares outstanding. The share issuance was non-cash, at a deemed price of US$6.00 per share (aggregate US$8,985,000), exchanged for 3,473 ordinary shares of the Reporting Person, and the Reporting Person may be deemed an affiliate and control person of the Issuer. The filing also discloses standstill restrictions and resale limitations under the Swap Agreement.

• · Reporting Person may be deemed an affiliate and control person of the Issuer, with a standstill restricting proxy solicitation, board changes, and business combination proposals while it holds any Issuer shares
• · Additional Shares are unregistered under the Securities Act and subject to resale restrictions and restrictive legends
• · Filing references an Original Schedule 13D dated June 3, 2026 and Subject Shares acquired Feb 25, 2026 via an irrevocable put option
• · Consideration was non-cash on both sides, and the Swap Agreement states no cash was paid for the Additional Shares

15-10-2026

GNK Holdings LLC, Nachum Klugman, and Gabrielle Philipson filed Amendment No. 2 to their Schedule 13D on Reliance Global Group, Inc. (RELIW), disclosing that Ms. Philipson bought 30,944 additional shares on October 15, 2026 for about $70,861.76 (roughly $2.29 per share), bringing the group's beneficial ownership to 197,905 shares, or approximately 11.78% of the 1,679,936 shares outstanding as of August 26, 2026. The same day, the reporting persons delivered a Florida Business Corporation Act demand for a special shareholder meeting to remove all five current directors without cause and elect five nominees, along with a shareholder records inspection demand and a Rule 14a-7 request; they also intend to solicit proxies and, if successful, pursue a strategic review, a review of the White Lion Capital equity line, and disciplined capital allocation. The filing is a contested-control development and carries no reported financial results, so the positive buying signal is weighed against the uncertainty of a proxy contest and the absence of any agreed compensation or issuer response.

• · Ms. Philipson funded the October 15, 2026 purchases with personal funds, including margin borrowing
• · All 197,905 shares are held in Ms. Philipson's individual brokerage account; no reporting person has sole voting or dispositive power
• · Each nominee has agreed to be named in proxy materials and to serve if elected
• · No compensation for the proposed Executive Chairman role has been agreed
• · The reporting persons state they may acquire or dispose of securities or change their plans at any time
• · The amendment corrects prior ownership figures and the cover page

15-10-2026

Elysia Capital I SCSp and its ultimate beneficial owner Stefano Buono filed a Schedule 13G disclosing passive beneficial ownership in newcleo plc (formerly newcleo Ltd.). Elysia Capital I SCSp reports 19,210,290 Ordinary Shares, or 6.8% of the 281,534,950 shares outstanding, while Stefano Buono reports 20,123,335 shares, or 7.1% including options exercisable within 60 days. The filing is made under Rule 13d-1(d), which applies to passive holders not seeking control, and the filing date is October 15, 2026, with an event date of September 21, 2026.

• · Elysia Capital I SCSp is a Luxembourg special limited partnership whose general partner is Elysia GP S.a r.l.
• · Elysia Capital I SCSp holds sole voting and dispositive power over its 19,210,290 shares, exercised through its general partner.
• · Stefano Buono disclaims beneficial ownership of the Elysia-held shares except to the extent of his pecuniary interest.
• · The filing was made under Rule 13d-1(d), which is typically used by passive investors not seeking control of the issuer.
• · A Joint Filing Agreement under Rule 13d-1(k)(1) is included as Exhibit 99.1.
• · The issuer's name changed from newcleo Ltd. to newcleo plc on April 24, 2026, per the filing header.
• · The subject company is headquartered at 55 South Audley Street, London, and the filers are based in Luxembourg and Turin, Italy.

15-10-2026

Working Capital Advisors (UK) Ltd. and affiliated reporting persons (Working Capital Partners, Ltd., Working Capital Management Pte. Ltd., and Kenneth Chan) filed Amendment No. 6 to Schedule 13G on October 15, 2026, disclosing beneficial ownership of 4,848,534 shares of Stitch Fix, Inc. Class A Common Stock, representing 4.1% of the class as of October 13, 2026. The filing is a passive ownership disclosure under Rule 13d-1(c) with a certification that the shares are not held to influence control of the issuer.

• · Filing is Amendment No. 6 to the Schedule 13G, filed under Rule 13d-1(c) (passive investor status).
• · Reporting persons hold 0 shares with sole voting power and 4,848,534 shares with shared voting power and shared dispositive power.
• · Working Capital Partners, Ltd. (Cayman Islands) is the fund; Working Capital Advisors (UK) Ltd. is its investment manager.
• · Reporting persons certify the securities were not acquired and are not held to change or influence control of the issuer.

15-10-2026

Liontrust Investment Partners LLP filed a Schedule 13D reporting beneficial ownership of 5,194,322 shares of MaxCyte, Inc. (MXCT), representing 5.0% of the outstanding class (5.0330% per the filing). The filing discloses a series of open-market sales between September 1 and September 14, 2026 and a return to net buying on October 14, 2026, with the position crossing the 5% reporting threshold. Holdings are reported as shared, with no sole voting or dispositive power.

• · Filing is a Schedule 13D (not 13G), indicating the reporting person holds the position with an intent that may go beyond passive investment; the Item 4 purpose disclosure was not included in the excerpt provided.
• · Between September 1 and September 14, 2026, Liontrust sold shares on eight trading days, with prices ranging from roughly $1.15 to $1.27 per share.
• · A further sale of 3,111 shares occurred on October 7, 2026 at about $1.05 per share, the lowest price in the disclosed series.
• · On October 14, 2026, Liontrust bought 356,946 shares in three transactions at a uniform price of $1.2607 per share, reversing the prior selling pattern.
• · Reported percentage ownership (5.0330%) is computed against the class outstanding; the filing does not state the denominator used.

15-10-2026

Bank of America Corporation and Banc of America Preferred Funding Corporation filed Amendment No. 7 to their Schedule 13D, reporting that Nuveen Minnesota Quality Municipal Income Fund (NMS) redeemed 20 of their adjustable rate MuniFund term preferred (AMTP) shares on October 13, 2026, at liquidation preference plus accrued unpaid dividends. The Reporting Persons now hold 478 AMTP shares, representing 100% of that preferred class, with no voting or dispositive power over other shares reported. This is a routine holding update driven by the issuer's redemption rather than a discretionary change in investment position.

• · The original Schedule 13D was dated October 6, 2014 and filed October 9, 2014; this is Amendment No. 7.
• · Schedule I and Schedule II were replaced, and Exhibits 99.1 (Joint Filing Agreement) and 99.2 (Power of Attorney) were updated.
• · Filing is made as a Schedule 13D/A under the Securities Exchange Act of 1934 and is signed October 15, 2026.

15-10-2026

JPMorgan Chase & Co. filed a Schedule 13G/A reporting beneficial ownership of 19,559,978 shares of Yum China Holdings, Inc. (YUMC) common stock as of September 30, 2026, representing 5.7% of the class. The holding comprises 15,029,199 shares with sole voting power and 19,319,810 shares with sole dispositive power, plus 240,168 shares with shared dispositive power. The filing is a routine passive-holder amendment under Rule 13d-1(b), with JPMorgan certifying the shares were acquired in the ordinary course of business and not to influence control.

• · Filing made under Rule 13d-1(b), indicating JPMorgan is filing as a qualified institutional holder (bank holding company, parent-level HC filer)
• · Shares reported with shared voting power (1,075,147) are a subset of the aggregate 19,559,978 reported, with the difference from sole dispositive power reflecting disaggregation across subsidiaries
• · Filing identifies eight JPMorgan subsidiaries and one additional entity (55I, LLC) as having acquired the reported securities
• · Filing is an amendment (13G/A) with LIVE status, indicating an update to a previously reported position rather than an initial stake disclosure

15-10-2026

JPMorgan Chase & Co. filed an amended Schedule 13G (SC 13G/A) disclosing beneficial ownership of 8,185,560 shares of Warner Music Group Corp. Class A Common Stock, representing 5.5% of the class as of September 30, 2026. The filing reports sole voting power over 7,517,874 shares, shared voting power over 139,565 shares, sole dispositive power over 8,185,556 shares, and 4.0% of the class held in aggregate by the reporting person's group. The filing is a routine passive-holding disclosure under Rule 13d-1(b) made by a bank holding company, with no stated intent to influence control.

• · Filing is made under Rule 13d-1(b), indicating a passive institutional holder certification rather than a 13D activist filing
• · Filer certifies shares were acquired and are held in the ordinary course of business without purpose or effect of changing or influencing control of WMG
• · Ownership is spread across multiple JPMorgan subsidiaries, including J.P. Morgan Securities LLC, JPMorgan Asset Management (UK) Limited, and JPMorgan Chase Bank, National Association
• · Filing identifies the parent holding company (HC) and reports no specific sole vs. shared breakdown beyond the figures listed above

15-10-2026

Johnson & Johnson Innovation - JJDC, Inc. (a wholly-owned subsidiary of Johnson & Johnson) filed a Schedule 13G reporting beneficial ownership of 1,475,302 shares of TRex Bio, Inc. Common Stock, equal to 5.3% of the outstanding shares, as of October 13, 2026. The filing is made under Rule 13d-1(c) as a passive holder, with a certification that the securities were not acquired to change or influence control of the issuer.

• · Filing type is Schedule 13G (LIVE), filed under Rule 13d-1(c), indicating a passive investor rather than an activist filer
• · J&J may be deemed to indirectly beneficially own the shares through its wholly-owned subsidiary JJDC; sole voting and dispositive power is reported for JJDC and J&J at 1,475302 shares each
• · The filing was executed with a Joint Filing Agreement (Exhibit A) between JJDC and J&J

15-10-2026

JPMorgan Chase & Co. filed an amended Schedule 13G reporting beneficial ownership of 4,824,775 shares of Corpay, Inc. (CPAY) common stock as of September 30, 2026, representing approximately 7.3% of the class. The filing is made under Rule 13d-1(b) by a bank holding company and includes a certification that the shares are held in the ordinary course of business and not for the purpose of influencing control. The filing is a routine passive-holder disclosure with no reported acquisition or disposition event beyond the updated holdings.

• · Filing made under Rule 13d-1(b), indicating a qualified institutional holder rather than an activist 13D filer
• · Filing is a 13G/A amendment with a 'LIVE' amendment type, reflecting a change in previously reported holdings
• · Subject company CUSIP is 219948106; filer is classified as a bank holding company (SIC 6021)
• · Corpay was formerly known as FleetCor Technologies Inc (name change dated 2002)

15-10-2026

JPMorgan Chase & Co. filed a Schedule 13G/A reporting beneficial ownership of Silgan Holdings Inc. common stock as of September 30, 2026. The filing discloses sole voting power over 6,070,112 shares (2.0%), shared voting power over 6,242,849 shares (2.0%), and aggregate beneficial ownership of 6,242,851 shares representing 5.9% of the class. The filing is a routine passive-holder disclosure made under Rule 13d-1(b) with a certification that the shares are held in the ordinary course of business and not to influence control.

• · Event date of September 30, 2026; filed October 15, 2026
• · Filing made under Rule 13d-1(b), indicating a passive institutional holder status
• · Silgan is classified under SIC 3411 (Metal Cans); fiscal year end December 31

15-10-2026

JPMorgan Chase & Co. filed an amended Schedule 13G reporting beneficial ownership of 5,617,083 shares of Levi Strauss & Co. Class A Common Stock as of September 30, 2026, representing 5.6% of the class. The filing is a passive, ordinary-course disclosure under Rule 13d-1(b) with no control intent, and it reports no change in control or any regulatory action.

• · Filing type is a Schedule 13G/A filed under Rule 13d-1(b), indicating a qualified institutional holder certifying no intent to influence control.
• · Event date for the reported holdings is 09/30/2026; the filing itself is dated 10/15/2026.
• · Of the 5,617,083 shares, 5,355,105 carry sole voting power and 5,596,684 carry sole dispositive power, with no shared voting or dispositive power reported.

15-10-2026

JPMorgan Chase & Co. filed a Schedule 13G/A reporting beneficial ownership of 5,300,390 shares of Neurocrine Biosciences common stock as of September 30, 2026, representing 5.2% of the class. The filing is a passive institutional disclosure made under Rule 13d-1(b) by a bank holding company, with sole voting power over 4,725,485 shares and sole dispositive power over 5,294,407 shares. No change in control intent is asserted, and the filing contains no operational, financial, or guidance information about Neurocrine itself.

• · Filing is an amendment (13G/A) with a 09/30/2026 event date, disclosed October 15, 2026.
• · Holdings are aggregated across multiple JPMorgan subsidiaries, including J.P. Morgan Securities LLC, JPMorgan Chase Bank N.A., and several asset management entities.
• · Filer certifies the shares were acquired and held in the ordinary course of business without intent to influence control of the issuer.

15-10-2026

Laurence W. Lytton filed a Schedule 13G reporting beneficial ownership of 617,207 shares of Retension Pharmaceuticals, Inc. common stock, representing 7.4% of the 8,331,599 shares outstanding following the Issuer's initial public offering closing on October 13, 2026. The filing is a passive ownership disclosure under Rule 13d-1(c), with the reporting person certifying the shares are not held to influence or change control of the issuer.

• · Ownership percentage is calculated against shares outstanding after the October 13, 2026 IPO closing, as stated in the Issuer's Prospectus filed October 9, 2026
• · Reporting person holds sole voting and sole dispositive power over all 617,207 reported shares
• · Filing made under Rule 13d-1(c), indicating a passive investor certification rather than an activist 13D filing
• · Issuer's CIK is 0002002988 with Delaware incorporation; the Issuer's business address is c/o Redux Therapeutics, LLC in McLean, VA